Share

EORTC organizing session on Cancer and Employment at European Business Summit 2015 in Brussels

European Business Summit, Europe’s key meeting place for business leaders and decision makers, is the debate platform where Business and Politics Shape the Future. Every year, the EBS attracts more than 2000 participants from over 60 countries, including: the President of the European Commission, members of the European Commission, members of the European Parliament, Heads of State, CEOs, high-ranking individuals and about 200 journalists and broadcasters. After the steam engine, mass production and automation, the fourth industrial revolution is on its way, fueled by the digitalisation. Under the theme ‘Europe 4.0 – Delivering a vision for the future of Europe’, EBS 2015 will focus on how the industry and the society are impacted by the digitalisation.

The EORTC is organizing a session at EBS 2015 on “Cancer Survivorship & Employment Session: How can businesses tackle new societal issues?” on 6 May 2015 at Palais d’Egmont, Brussels, from 14:30 to 16:30 in the presence of H.R.H Princess Astrid of Belgium.

This unique session will be Chaired by Françoise Meunier, Director Special Projects, EORTC, and M. Vermaerke , CEO FEBELFIN, and moderated by Andrew Jack of the Financial Times and Peter O’Donnell of the European Voice. The program includes a keynote lecture by Marianne Thyssen, EU Commissioner Employment, Social affairs, Skills and Labor Mobility, and presentations by Isabelle Lebrocquy, Cancer Survivor, Patient Advocate and Social Entrepreneur, Richard Ellis, Director of Corporate Social Responsibilities, Walgreens Boots Alliance, Ingrid Kössler, European Economic and Social Committee, and Ingrid Klingmann, Chairman, European Forum for Good Clinical Practice.

Indeed, the success cancer clinical research has achieved over the past 40 years has created unique challenges. Many cancer patients now become cancer survivors and are confronted with unanticipated societal problems related to quality of life or obtaining mortgages, appropriate insurance, or gainful employment. Consequently, the EORTC is also focusing attention on cancer survivorship and addressing challenges faced by patients cured of cancer.

The First EORTC Cancer Survivorship Summit held in January 2014 was a great success and sensitized participants from all walks of life on a variety of problems faced by cancer survivors after being cured from cancer. These include finding or keeping a job, obtaining a mortgage or insurance, etc.

Register for the European Business Summit. Registration requests are subject to approval by the European Business Summit Organizers.

Visit EBS 2015 for more information.

Program of the session in the presence of H.R.H Princess Astrid of Belgium

14:00-14:30 CHAIRING THE SESSION: Françoise Meunier, Director Special Projects, EORTC (BE) and M. Vermaerke , CEO FEBELFIN (BE)

 

14:30-16:30 MODERATORS: Andrew Jack, Financial Times (GB) & Peter O’Donnell, European Voice (BE)
WELCOME: Françoise Meunier, Director Special Projects, EORTC (BE)
KEYNOTE LECTURE
Marianne Thyssen, EU Commissioner Employment, Social affairs, skills and labour mobility (BE)
PRESENTATIONS
Isabelle Lebrocquy, Cancer Survivor, Patient Advocate and Social Entrepreneur (O Puce), NL
Richard Ellis, Director of Corporate Social Responsibilities, Walgreens Boots Alliance, GB
Ingrid Kössler, European Economic and Social Committee, SE
Ingrid Klingmann, Chairman, European Forum for Good Clinical Practice (EFGCP), BE
DEBATE

 

16:30 End of the session

 

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023